Multiple myeloma remains one of the most complex hematologic malignancies to manage, not because effective drugs are lacking, but because the rapidly expanding therapeutic arsenal has made sequencing decisions increasingly consequential for long-term survival outcomes. A comprehensive review in the New England Journal of Medicine addresses exactly this challenge, offering a framework that practicing clinicians and patients alike need as treatment paradigms shift away from one-size-fits-all protocols.
The review, spanning pages 992–1008 of NEJM's September 2026 issue, synthesizes current evidence across induction regimens, consolidation strategies, maintenance therapy, and the integration of novel agents including bispecific antibodies and CAR-T cell therapies. It critically evaluates how transplant eligibility, cytogenetic risk stratification, and measurable residual disease (MRD) status should drive individualized decision-making. Particular attention is paid to how depth of response—specifically MRD negativity—is increasingly informing whether patients can safely de-escalate or discontinue maintenance, a question with profound quality-of-life implications.
The broader significance of this review lies in its timing. Over the past five years, the myeloma treatment landscape has been fundamentally restructured by the clinical approval of daratumumab-based quadruplet induction, BCMA-targeted bispecifics, and multiple CAR-T platforms—each generating compelling response rates but also introducing new toxicity profiles and sequencing dilemmas. What was standard of care in 2020 is already being reconsidered. The NEJM's choice to publish a dedicated decision-framework review signals that clinical consensus is crystallizing around MRD-adapted and risk-stratified approaches rather than fixed-duration protocols.
From a longevity standpoint, myeloma is increasingly a disease patients live with for a decade or more, making early treatment architecture decisions disproportionately important. Limitations of the current evidence base include the relative paucity of head-to-head trials comparing novel agent sequences and limited long-term follow-up data for the newest cellular therapies. This is a paradigm-consolidating piece rather than a single disruptive finding, but its synthesis value for clinicians navigating a fragmented evidence base is substantial.